Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma

Neuroendocrinology Letters

Volumn 28, Issue 3, 2007, Pages 221-229

  Brzezlańska, Ewa ^a,b   Pastuszak Lewandoska, Dorota ^a,b   Lewiński, Andrzej ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Chromosome rearrangements; Human papillary thyroid carcinoma; NTRK1 oncogene; NTRK1 tyrosine kinase receptor; Trk sequences

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; FOCAL ADHESION KINASE 1; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 3; PROTEIN TYROSINE KINASE A; TRANSFORMING RECEPTOR KINASE 2H; TRANSFORMING RECEPTOR KINASE T1; TRANSFORMING RECEPTOR KINASE T2; TRANSFORMING RECEPTOR KINASE T3; TROPOMYOSIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CANCER STAGING; CLINICAL FEATURE; DISEASE ASSOCIATION; GENE ACTIVATION; GENE FREQUENCY; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC CORRELATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; INCIDENCE; LATENT PERIOD; ONCOGENE; OUTCOMES RESEARCH; PROTEIN DOMAIN; PROTO ONCOGENE; RADIATION RESPONSE; REVIEW; SEQUENCE ANALYSIS; SEX DIFFERENCE; THYROID PAPILLARY CARCINOMA;

EID: 34447266709     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Beimfohr C, Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM (1999). NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int J Cancer. 80: 842-847.
2. Bibel M, Barde YA (2000). Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 14: 2919-2937.
3. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, et al. (1996). Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab. 81: 2006-2009.
4. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA (1998). RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 4: 223-228.
5. Bounacer A, Schlumberger M, Wicker R, Du-Villard JA, Caillou B, Sarasin A, et al. (2000). Search for NTKR1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation. Br J Cancer. 82: 308-314.
6. Brzeziańska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Włoch J, Lewiński A (2006). Molecular analysis of RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat Res. 599: 26-35.
7. Butti MG, Bongarzone I, Ferraresi G, Mondellini P, Borrello MG, Pierotti MA (1995). A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics. 28: 15-24.
8. Collins BJ, Chiappetta G, Schneider AB, Santoro M, Pentimalli F, Fogelfeld L, et al. (2002). RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. J Clin Endocrinol Metab. 87: 3941-3946.
9. Cordon-Cardo C, Tapley P, Jing SQ, Nanduri V. O'Rourke E, Lamballe F, et al. (1991). The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell. 66: 173-183.
10. Coulier F, Martin-Zanca D, Ernst M, Barbacid M (1989). Mechanism of activation of the human trk oncogene. Mol Cell Biol. 9: 15-23.
11. Delvincourt C, Patey M, Flament JB, Suarez HG, Larbre H, Jardillier JC et al. (1996). Ret and trk proto-onkogene activation in thyroid papillary carcinomas in French patients from the Champagne-Ardenne region. Clin Biochem. 29: 267-271.
12. Ehrhard PB, Ganter U, Stalder A, Bauer J, Otten U (1993). Expression of functional trk protooncogene in human monocytes. Proc Nat Acad Sci USA. 90: 5423-5427.
13. Farid NR, Shi Y, Zou M (1994). Molecular basis of thyroid cancer. Endocr Rev. 15: 202-232.
14. Gimm O, Dziema H, Brown J, de la Puente A, Hoang-Vu C, Dralle H, et al. (2001). Mutation analysis of NTRK2 and NTRK3, encoding 2 tyrosine kinase receptors, in sporadic human medullary thyroid carcinoma reveals novel sequence variants. Int J Cancer. 92: 70-74.
15. Gimm O (2001). Thyroid cancer. Cancer Lett. 163: 143-156.
16. Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, et al. (1998). Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene. 16: 809-816.
17. Greco A, Mariani C, Miranda C, Lupas A, Pagliardini S, Pomati M. et al. (1995). The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol. 15: 6118-6127.
18. Greco A, Mariani C, Miranda C, Pagliardini S, Pierotti MA (1993). Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes. Genomics. 18: 397-400.
19. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA (1997). Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer. 19: 112-123.
20. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C, Della Porta G (1992). TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene. 7: 237-242.
21. Greco A, Roccato E, Pierotti MA (2004). TRK oncogenes in papillary thyroid carcinoma. Cancer Treat Res. 122: 207-219.
22. Greco A, Villa R, Pierotti MA (1996). Genomic organization of the human NTRK1 gene. Oncogene. 13: 2463-2466.
23. Hunt JL (2005). Unusual thyroid tumors: a review of pathologic and molecular diagnosis. Exp. Rev. Mol. Diagn. 5: 725-734.
24. Indo Y, Mardy S, Tsuruta M, Karim MA, Matsuda I (1997). Structure and organization of the human TRKA gene encoding a high affinity receptor for nerve growth factor. Jpn J Hum Genet. 42: 343-351.
25. Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, et al. (1996). Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 13: 382-383.
26. Indo Y (2002). Genetics of congenital insensitivity to pain with anhidrosis (CIPA) or hereditary sensory and autonomic neuropathy type IV. Clinical, biological and molecular aspects of mutations in TRKA(NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Clin Auton Res. 12: 120-132.
27. Indo Y (2001). Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in TRKA (NTRKI) gene encoding the receptor tyrosine kinase for nerve growth factor. Hum Mutat. 18: 462-471.
28. Ip NY, Stitt TN, Tapley P, Klein R, Glass DJ, Fandl J, et al. (1993). Similarities and differences in the way neurotrophins interaction with the Trk receptors in neuronal and nonneuronal cells. Neuron. 10: 137-149.
29. Jarzab B, Włoch J, Wiench M (2001). Molecular changes in thyroid neoplasia. Folia Histochem Cytobiol. 39: 26-27.
30. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF (1991). The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science. 252: 554-558.
31. Karbownik M, Brzeziańska E, Lewiński A (2005). Increased expression of mRNA specific for thymidine kinase, deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma. Cancer Lett. 225: 267-273.
32. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM (1995). High prevalence of RET rearrangement in thyroid tumours of children from Belarus after the Chernobyl reactor accident. Oncogene. 11: 2459-2467.
33. Kuo CS, Lin CY, Hsu CW, Lee CH, Lin HD (2000). Low frequency of rearrangement of TRK protooncogene in Chinese thyroid tumors. Endocrine. 13: 341-344.
34. Lewiński A, Ferenc T, Sporny S, Jarzab B (2000). Thyroid carcinoma: diagnostic and therapeutic approach; genetic background. Endocr Regul. 34: 99-113.
35. Liu RT, Chou FF, Wang CH, Lin CL, Chao FP, Chung JC, et al. (2005). Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/ PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese. Thyroid. 15: 326-335.
36. Mardy S, Miura Y, Endo F, Matsuda I, Indo Y (2001). Congenital insensitivity to pain with anhidrosis (CIPA): effects of TRKA (NTRK1) missense mutations on autophosphorylation of the receptor tyrosine kinase for nerve growth factor. Hum Mol Genet. 10: 179-188.
37. Mardy S, Miura Y, Endo F, Matsuda I, Sztriha L, Frossard P, et al. (1999). Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor. Am J Hum Genet. 64: 1570-1579.
38. Martin-Zanca D, Hughes SH, Barbacid M (1986). A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 319: 743-748.
39. Martin-Zanca D, Oskam R, Mitra G, Copeland T, Barbacid M (1989). Molecular and biochemical characterization of the human trk proto-oncogene. Mol Cell Biol. 9: 24-33.
40. Mencinger M, Panagopoulos I, Andreasson P, Lassen C, Mitelman F, Aman P (1997). Characterization and chromosomal mapping of the human TFG gene involved in thyroid carcinoma. Genomics. 41: 327-331.
41. Miki H, Kitaichi M, Masuda E, Komaki K, Yamamoto Y, Monden Y (1999). RET/ PTC expression may be associated with local invasion of thyroid papillary carcinoma. J Surg Oncol. 71: 76-81.
42. Miozzo M, Pierotti MA, Sozzi G, Radice P, Bongarzone I, Spurr NK et al. (1990). Human TRK proto-oncogene maps to chromosome 1q32-q41. Oncogene. 5: 1411-1414.
43. Miranda C, Minoletti F, Greco A, Sozzi G, Pierotti MA (1994). Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization. Genomics. 23: 714-715.
44. Mitra G, Martin-Zanca D, Barbacid M (1987). Identification and biochemical characterization of p70TRK, product of the human TRK oncogene. Proc Natl Acad Sci USA. 84: 6707-6711.
45. Miura Y, Hiura M, Torigoe K, Numata O, Kuwahara A, Matsunaga M, et al. (2000). Complete paternal uniparental isodisomy for chromosome 1 revealed by mutation analyses of the TRKA (NTRK1) gene encoding a receptor tyrosine kinase for nerve growth factor in patient with congenital insensitivity to pain with anhidrosis. Hum Genet. 107: 205-209.
46. Moretti F, Nanni S, Pontecorvi A (2000). Molecular pathogenesis of thyroid nodules and cancer. Baillieres Best Pract Res Clin Endocrinol Metab. 14: 517-539.
47. Morris CM, Hao QL, Heisterkamp N, Fitzgerald PH, Groffen J (1991). Localization of the TRK proto-oncogene to human chromosome bands 1q23-24. Oncogene. 6: 1093-1095.
48. Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J (2000). Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery. 128: 984-993.
49. Nikiforov YE (2002). RET/PTC rearrangement in thyroid tumours. Endocr Pathol. 13: 3-16.
50. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE (2000). Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 290: 138-141.
51. Ohan N, Sabourin D, Booth RA, Liu XJ (2000). Xenopus laevis TRK-fused gene (TFG) is an SH3 domain binding protein highly expressed in the cement gland. Mol Reprod Dev. 56: 336-344.
52. Pierotti MA, Bongarzone I, Borello MG, Greco A, Pilotti S, Sozzi G (1996). Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer. 16: 1-14.
53. Pierotti MA, Vigneri P, Bongarzone I (1998). Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Rec Res Cancer Res. 154: 237-247.
54. Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N (2003). Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol. 148: 505-513.
55. Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, et al. (2000). Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 6: 1093-1103.
56. Rabes HM (2001). Gene rearrangements in radiation-induced thyroid carcinogenesis. Med Pediatr Oncol. 36: 574-582.
57. Ranzi V, Meakin SO, Miranda C, Mondellini P, Pierotti MA, Greco A (2003). The signalling adapters Fibroblast Growth Factor Receptor Substrate 2 and 3 are activated by the thyroid TRK oncoproteins. Endocrinology. 144: 922-928.
58. Roccato E, Bresson P, Sabatella G, Rumio C, Vizzotto L, Pierotti MA et al. (2005). Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 65: 2572-2576.
59. Roccato E, Miranda C, Raho G, Pagliardini S, Pierotti MA, Greco A (2005). Analysis of SHP-1-mediated down-regulation of the TRK-T3 oncoprotein identifies Trk-fused gene (TFG) as a novel SHP-1-interacting protein. J Biol Chem. 280: 3382-3389.
60. Roccato E, Miranda C, Ranzi V, Gishizki M, Pierotti MA, Greco A (2002). Biological activity of the thyroid Trk-T3 oncogene requires signalling through Shc. Br J Cancer. 87: 645-653.
61. Roccato E, Pagliardini S, Cleris L, Canevari S, Formelli F, Pierotti MA et al. (2003). Role of TFG sequences outside the coiled-coil domain in TRK-T3 oncogenic activation. Oncogene. 22: 807-818.
62. Russell JP, Powell DJ, Cunnane M, Greco A, Portella G, Santoro M et al. (2000). The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene. 19: 5729-5735.
63. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G (2002). Molecular mechanisms of RET activation in human cancer. Ann NY Acad Sci. 963: 116-121.
64. Shatzky S, Moses S, Levy J, Pinsk V, Hershkovitz E, Herzog L et al. (2000). Congenital insensitivity to pain with anhidrosis (CIPA) in Israeli-Bedouins: genetic heterogeneity, novel mutations in the TRKA /NGF receptor gene, clinical findings, and results of nerve conduction studies. Am J Med Genet. 92: 353-360.
65. Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A et al. (1994). Severe sensory and sympathetic neuropathies in mice carrying disrupted Trk/NGF receptor gene. Nature. 368: 246-249.
66. Suarez HG (2000). Molecular basis of epithelial thyroid tumorigenesis. CR Acad Sci III. 323: 519-528.
67. Wajjwalku W, Nakamura S, Hasegawa Y, Miyazaki K, Satoh Y, Funahashi H et al. (1992). Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res. 83: 671-675.
68. Weier HU, Rhein AP, Shadravan F, Collins C, Polikoff D (1995). Rapid physical mapping of the human Trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy. Genomics. 26: 390-393.
69. Wiench M, Włoch J, Oczko M, Gubała E, Jarzab B (2001). Rearrangement of the RET gene in papillary thyroid carcinoma. Wiad Lek. 54: 64-71.
70. Yan Ch, Liang Y, Nylander KD, Schor NF (2002). TrkA as a life and death receptor: receptor dose as a Mediator of function. Cancer Res. 62: 4867-4875.
71. Ziemiecki A, Muller RG, Fu XC, Hynes NE, Kozma S (1990). Oncogenic activation of the human trk proto-oncogene by recombination with the ribosomal large subunit protein L7a. EMBO J. 9: 191-196.